CHOP Versus CHOP Plus ESHAP and High-Dose Therapy with Autologous Peripheral Blood Progenitor Cell Transplantation for High-Intermediate–Risk and High-Risk Aggressive Non-Hodgkin's Lymphoma

2000 ◽  
Vol 1 (3) ◽  
pp. 219-225 ◽  
Author(s):  
Tanin Intragumtornchai ◽  
Wichai Prayoonwiwat ◽  
Tontanai Numbenjapon ◽  
Noppadol Assawametha ◽  
Rutchanee O'Charoen ◽  
...  
Keyword(s):  
High Risk ◽  
Cell Transplantation ◽  
Peripheral Blood ◽  
Progenitor Cell ◽  
Peripheral Blood Progenitor Cell ◽  
Hodgkin's Lymphoma ◽  
High Dose ◽  
Intermediate Risk ◽  
High Dose Therapy ◽  
Dose Therapy

scholarly journals High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma

1997 ◽  
Vol 8 (3) ◽  
pp. 243-246 ◽  
Author(s):  
H. Goldschmidt ◽  
U. Hegenbart ◽  
M. Wallmeier ◽  
S. Hohaus ◽  
R. Engenhart ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Cell Transplantation ◽  
Peripheral Blood ◽  
Progenitor Cell ◽  
Peripheral Blood Progenitor Cell ◽  
High Dose ◽  
High Dose Therapy ◽  
Dose Therapy

scholarly journals High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma

Blood ◽  
1989 ◽  
Vol 74 (4) ◽  
pp. 1260-1265 ◽  
Author(s):  
A Kessinger ◽  
JO Armitage ◽  
DM Smith ◽  
JD Landmark ◽  
PJ Bierman ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Peripheral Blood ◽  
Hodgkin's Lymphoma ◽  
High Dose ◽  
Event Free Survival ◽  
High Dose Therapy ◽  
Free Survival ◽  
Dose Therapy

Abstract Forty patients with refractory Hodgkin's disease (24 patients) or non- Hodgkin's lymphoma (16 patients) who were considered for high-dose therapy but not for autologous bone marrow transplantation (ABMT) due to BM metastases, previous pelvic irradiation, a history of marrow involvement by tumor or hypocellular marrow in conventional harvest sites received high-dose therapy and autologous peripheral blood (PB) hematopoietic stem cell transplantation. Disappearance of circulating neutrophils and development of RBC and platelet transfusion-dependence was followed, in the evaluable patients, by reappearance of 0.5 x 10(9)/L circulating granulocytes and sufficient platelets to obviate the need for platelet transfusions at a median of 25 days after transplantation. Twenty-three patients experienced a clinical complete remission (CR). The projected 2-year event-free survival was 24% for all 40 patients and 49% for the non-Hodgkin's lymphoma patients. The projected 18-month event-free survival for the Hodgkin's disease patients was 15%. PB stem cell transplantation provided an opportunity to administer high-dose salvage therapy to patients with refractory lymphoma who otherwise were not candidates for such therapy. For some of those patients, the high-dose therapy produced prolonged survival, free of tumor progression.

Sign in / Sign up

Export Citation Format

Share Document